Revvity Shorts Retreat Further as Options Turn Defensive

RVTY is covering faster than usual into Wednesday's print, now sitting at its lowest short interest level in at least a year.

Short sellers have continued to retreat since the previous preview was published on October 31. The position has fallen a further 3.5% in a single session, bringing short interest to 5.1% of free float, with the weekly decline of nearly 14% running roughly 1.7 standard deviations below the stock's typical weekly move. The borrow market reflects no urgency on the short side: cost to borrow is a negligible 0.46%, down about 8% on the week, and availability has expanded sharply to 688% of outstanding short interest, up 55% over the past week alone. That is the loosest it has been all year against a 52-week trough of 156%. Nothing in the lending market suggests bearish conviction.

The options market, however, tells a more defensive story. The put/call ratio jumped to 0.89 on November 3, nearly three standard deviations above its 20-day average of 0.61. That is the most skewed toward protection the options market has been in recent months, and it arrived on the same day the stock surged 7.8%, closing at $163.48. The divergence is notable: shorts are covering while options buyers are hedging. Revvity is up about 8% over the past month and has dramatically outperformed its peer group. ILMN fell 16% over the same week, FTRE dropped 16%, and MLAB lost 6%. Against that backdrop, Revvity's 1% weekly gain marks a clear divergence from sector pressure.

The fundamental debate remains unresolved. The bull case rests on roughly 80% recurring revenue, the momentum in Diagnostics (11% organic growth in Q2), and the Signals software platform, which serves 47 of the top 50 global pharma companies. Management has raised full-year organic growth guidance twice, now targeting 4% to 5%. Bears counter that the two largest businesses, Immunodiagnostics and Life Sciences Solutions, together around 70% of revenue, have not demonstrated the step-up to 6% to 8% growth that the long-range plan requires. Euroimmun and BioLegend have both lost momentum, and competitive pressure across reagents and AI-driven research software is rising. TD Cowen raised its target to $175 in mid-October while keeping a Buy, and Keybanc holds at $165 Overweight, but the consensus mean price target of $150 sits below the current price, reflecting a Street that has not fully caught up with the stock's move. UBS, which assumed coverage in September at Neutral with a $140 target, is now well below the market price.

T. Rowe Price remains the dominant holder with just over 21% of shares, and its two separate entities filed 13G amendments as recently as October 7 showing a combined stake that has grown materially. The insider register shows only routine 10b5-1 plan sales in recent months, all small and pre-scheduled, with no open-market buying or selling that would signal anything about management's view of the upcoming print.

The report will test whether Revvity's Q3 numbers can bridge the gap between a consensus that has not fully re-rated and a stock price that already has.